Membrane fusogenic nanoparticle‐based HLA‐peptide‐addressing universal T cell receptor‐engineered T (HAUL TCR‐T) cell therapy in solid tumor

Membrane fusogenic nanoparticle‐based HLA‐peptide‐addressing universal T cell receptor‐engineered T (HAUL TCR‐T) cell therapy in solid tumor

Abstract T cell receptor‐engineered T (TCR‐T) cell therapy has demonstrated therapeutic effects in basic research and clinical trials for treating solid tumors. Due to the peptide‐dependent recognition and the human leukocyte antigen (HLA)‐restriction, TCR‐T cell therapy is generally custom designed...

Full description

Bibliographic Details
Main Authors: Ruihan Xu, Qin Wang, Junmeng Zhu, Yuncheng Bei, Yanhong Chu, Zhichen Sun, Shiyao Du, Shujuan Zhou, Naiqing Ding, Fanyan Meng, Baorui Liu
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Bioengineering & Translational Medicine
Subjects:
HLA‐peptide complex
membrane fusogenic nanoparticles
solid tumors
TCR‐T cell therapy
tumor cell membrane modification
Online Access:https://doi.org/10.1002/btm2.10585

Internet

https://doi.org/10.1002/btm2.10585

Similar Items